The History of Terrorism
Preview
Open in TheBrain
Sofosbuvir (Sovaldi)
Attachments
Sofosbuvir
Parents
1987-Today Gilead Sciences (NASDAQ: GILD)
Breakthrough therapy
Drugs for Hepatitis C
Hepatitis C
John C. Martin (businessman)
NS5B (polymerase) inhibitors
Organofluorides
Prodrugs
Propionates
Pyrimidinediones
Specialty drugs
World Health Organization essential medicines
Children
2014 Martin is credited with taking Sovaldi from "zero-to-blockbuster in a couple of months" with profits topping $10 billion for 2014.
2020 Rolling Stone - Big Pharma's Covid-19 Profiteers How the race to develop treatments and a vaccine will create a historic windfall for the industry - and everyone else will pay the price
That O'Day might come to such a conclusion was not outlandish. Gilead became infamous a few years ago for charging $84,000 per course of treatment for Sovaldi, a "groundbreaking" hepatitis-C drug.